Cipher Pharmaceuticals Inc. (NASDAQ:CPHR; TSX:CPH) today announced that Shawn Patrick O'Brien, President and Chief Executive Officer, will present at the Jefferies 2015 Global Healthcare Conference in

Cipher Pharmaceuticals Inc. (NASDAQ:CPHR; TSX:CPH) ("Cipher" or "the Company"), in accordance with Toronto Stock Exchange requirements, announced the voting results from its Annual and Special...

– Company Achieves Significant Progress Across All Three Components of Growth Strategy – MISSISSAUGA, ON, May 13, 2015 /CNW/ - Cipher Pharmaceuticals Inc. (NASDAQ:CPHR; TSX:CPH) ("Cipher" or...

Cipher Pharmaceuticals Inc. (NASDAQ:CPHR; TSX:CPH) ("Cipher" or "the Company") today announced it has strengthened its Canadian dermatology portfolio by acquiring the Canadian rights to Vaniqa®...

Cipher Pharmaceuticals Inc. (NASDAQ:CPHR; TSX:CPH) today announced it will host a conference call for its Q1 2015 financial results and hold its Annual and Special Meeting of Shareholders on...

Cipher Pharmaceuticals Inc. (NASDAQ:CPHR; TSX:CPH) ("Cipher" or "the Company") today announced that the Court has issued an opinion in the claim construction hearing (commonly referred to as a...

Cipher Pharmaceuticals Inc. (NASDAQ:CPHR; TSX:CPH) today announced that Shawn Patrick O'Brien, President and Chief Executive Officer, will present at the Bloom Burton & Co. Healthcare Investor...

Accelerates development of a leading North American dermatology company Adds U.S. commercial infrastructure for our acquisition/in-licensing activities Raises US$100 million Senior Notes to...

Cipher Pharmaceuticals Inc. (NASDAQ:CPHR; TSX:CPH) today announced that Shawn Patrick O'Brien, President and Chief Executive Officer, will participate at the Laurentian Bank Securities 2nd Annual...

Cipher Pharmaceuticals Inc. (NASDAQ:CPHR; TSX:CPH) ("Cipher" or "the Company") today announced it has licensed the Canadian distribution rights to CF101, a novel chemical entity being developed by...